Eli Lilly chairman, president and CEO John Lechleiter has called for greater collaboration and communication between the German government and its healthcare system.
Lechleiter made the calls during an address at the Federation of German Industries Conference, and claimed that collaboration could increase innovation and help meet growing healthcare demands.
Labelling Germany as a pharmaceutical powerhouse, Lechleiter added: “Recent healthcare reforms are jeopardising the country’s legacy of pharmaceutical innovation. At the same time, I see Germany as a place where the pharmaceutical industry can achieve a breakthrough.”
Lechleiter cited the German Government’s decision to freeze prices for pharmaceuticals while also increasing mandatory rebates that the industry pays to the health system on sales as having potentially serious effects on the pharmaceutical industry.
Germany’s new AMNOG law, a new regulatory mechanism designed to assess benefits of new products entering the German market, also faced swift criticism, with Lechleiter claiming that it could cause significant delays to new medicine launches and damage innovation.